NI-16 RESPONSE ASSESSMENT OF BEVACIZUMAB THERAPY FOR GLIOBLASTOMA BY USING MULTIPLE PET TRACERS

Abstract Objective PET scans are useful for the diagnosis and treatment planning of glioma. Introduced in 2013, bevacizumab (Bev) efficacy can be difficult to determine using MRI imaging. We instead performed Bev-based glioblastoma treatment. Methods Eighty patients treated with Bev from July 2013 December 2021 were included. The divided into following three groups: first group received added Stupp regimen after biopsy or subtotal resection (first-dose group), second followed by tumor (neoadjuvant third TMZ + at recurrence (recurrent group). (FDG, MET, FLT, FMISO) before 4 weeks start FDG, FLT measured tumor-to-normal ratio (TNR), FMISO tumor-to-blood (TBR), as well percent change SUVmax, TNR, TBR, MTV Using Cox proportional hazards model, we examined which these rates prognostic factors. Results median PFS (months) OS 8.87, 16.53, 4.0 12.53, 22.13, 8.0, respectively. Significant differences first-line group, FDG TNR TBR recurrent MET neoadjuvant shown model. Conclusion Neoadjuvant prolonged OS. decrease rate TBR.